-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Imago BioSciences (NASDAQ:IMGO) Stock Price Up 7.7%
Imago BioSciences (NASDAQ:IMGO) Stock Price Up 7.7%
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares shot up 7.7% during trading on Friday . The stock traded as high as $15.33 and last traded at $15.32. 149 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 198,391 shares. The stock had previously closed at $14.23.
Analysts Set New Price Targets
Separately, HC Wainwright dropped their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Price Performance
The company has a market cap of $533.46 million and a PE ratio of -8.21. The stock has a fifty day moving average price of $16.04 and a 200-day moving average price of $17.41.
Insider Activity at Imago BioSciences
In other news, insider Jennifer Peppe sold 5,598 shares of the company's stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the transaction, the insider now owns 148,809 shares in the company, valued at approximately $2,888,382.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 8,168 shares of company stock valued at $155,402. Company insiders own 14.90% of the company's stock.Institutional Investors Weigh In On Imago BioSciences
A number of institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY acquired a new stake in shares of Imago BioSciences during the 1st quarter valued at about $28,000. Ameritas Investment Partners Inc. lifted its stake in Imago BioSciences by 108.3% in the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock valued at $30,000 after acquiring an additional 809 shares during the last quarter. Amalgamated Bank bought a new stake in Imago BioSciences in the first quarter worth approximately $41,000. Legal & General Group Plc grew its position in Imago BioSciences by 46.2% in the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after acquiring an additional 1,926 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Imago BioSciences during the 2nd quarter worth $119,000. Institutional investors and hedge funds own 99.50% of the company's stock.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Featured Stories
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares shot up 7.7% during trading on Friday . The stock traded as high as $15.33 and last traded at $15.32. 149 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 198,391 shares. The stock had previously closed at $14.23.
意馬生物科學公司(納斯達克代碼：IMGO-GET Rating)的股價在週五的交易中飆升了7.7%。該股盤中一度漲至15.33美元，最新報15.32美元。午盤交易中，149股股票易手，較198,391股的平均成交量下降了100%。該股此前收盤價為14.23美元。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, HC Wainwright dropped their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.
另外，在8月16日(星期二)的一份研究報告中，HC Wainwright將Imago BioSciences的目標價從36.00美元下調至35.00美元，並對該股設定了“買入”評級。
Imago BioSciences Price Performance
Imago BioSciences性價比
The company has a market cap of $533.46 million and a PE ratio of -8.21. The stock has a fifty day moving average price of $16.04 and a 200-day moving average price of $17.41.
該公司市值為5.3346億美元，市盈率為-8.21。該股的50日移動均價為16.04美元，200日移動均價為17.41美元。
Insider Activity at Imago BioSciences
Imago BioSciences的內部活動
Institutional Investors Weigh In On Imago BioSciences
機構投資者參與Imago BioSciences
A number of institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY acquired a new stake in shares of Imago BioSciences during the 1st quarter valued at about $28,000. Ameritas Investment Partners Inc. lifted its stake in Imago BioSciences by 108.3% in the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock valued at $30,000 after acquiring an additional 809 shares during the last quarter. Amalgamated Bank bought a new stake in Imago BioSciences in the first quarter worth approximately $41,000. Legal & General Group Plc grew its position in Imago BioSciences by 46.2% in the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after acquiring an additional 1,926 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Imago BioSciences during the 2nd quarter worth $119,000. Institutional investors and hedge funds own 99.50% of the company's stock.
一些機構投資者最近調整了對該股的持有量。紐約大都會人壽保險公司在第一季度收購了Imago BioSciences的新股，價值約2.8萬美元。今年第一季度，ameritas Investment Partners Inc.將其在Imago BioSciences的持股比例提高了108.3%。Ameritas Investment Partners Inc.在上個季度增持了809股後，現在持有1,556股該公司股票，價值3萬美元。合併銀行在第一季度購買了Imago BioSciences的新股份，價值約4.1萬美元。第二季度，Legal&General Group Plc在Imago BioSciences的地位增長了46.2%。Legal&General Group Plc在上個季度增持了1,926股後，現在擁有6,098股該公司股票，價值8.1萬美元。最後，瑞士信貸股份公司在第二季度收購了價值11.9萬美元的Imago BioSciences股票。機構投資者和對衝基金持有該公司99.50%的股票。
About Imago BioSciences
關於Imago BioSciences
(Get Rating)
(獲取評級)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
臨牀階段生物製藥公司Imago BioSciences，Inc.發現和開發了針對賴氨酸特異性脱甲基酶1(LSD1)的小分子產品候選產品，LSD1是一種用於生產骨髓中血細胞的酶。它的主要候選產品是Bomedemstat，正在進行第二階段臨牀試驗，用於治療骨髓增生性腫瘤和慢性骨髓癌，如骨髓纖維化、原發性血小板增多症和真性紅細胞增多症。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- 免費獲取StockNews.com關於Imago BioSciences(IMGO)的研究報告
- 霍梅爾在這些水平上看起來很便宜
- 露露檸檬將飆升至9月
- 耐克股票會被超賣，但仍被高估嗎？
- 美國鋁業是在第二季度業績強勁和更多股票回購之後買入的嗎？
- 皇家加勒比的寬帶合作能否推動收入增長？
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Imago BioSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧